Navigation Links
Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial
Date:7/22/2013

BOULDER, Colo., July 22, 2013 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq:   ARRY) will report top-line results from a placebo-controlled, randomized, double‑blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist and hold a conference call to discuss those results on Tuesday, July 23, 2013.  Ron Squarer, Chief Executive Officer, will lead the call.

(Logo:  http://photos.prnewswire.com/prnh/20121029/LA02195LOGO)Conference Call InformationDate: Tuesday, July 23, 2013Time: 

9:00 a.m. eastern timeToll-Free: 

(888) 771-4371Toll: 

(847) 585-4405Pass Code: 

35320183Webcast, including Replay and Conference Call Slides:  http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-irhomeAbout Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Array is evolving into a late-stage development company and currently expects significant progress toward generating data to support our upcoming Phase 3 / pivotal trial decisions.
Novartis began a Phase 3 trial evaluating Array-invented MEK162 in patients with NRAS-mutant melanoma in July 2013 and expects to begin a Phase 3 trial in patients with BRAF-mutant melanoma in 2013.  In addition, Array began a Phase 3 trial evaluating MEK162 in patients with low-grade serous ovarian cancer under the license agreement with Novartis in June 2013.  AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in patients with thyroid cancer in May 2013 and expects to begin a Phase 3 trial in patients with non-small cell lung cancer during the second half of 2013.  Three other Array-invented drugs are also approaching Phase 3 or pivotal trial decisions which are expected by the end of 2013. These include Array's wholly-owned drugs, ARRY-520 and ARRY-614, and one partnered program, danoprevir (with InterMune/Roche).  For more information on Array, please go to www.arraybiopharma.com.CONTACT:

Tricia Haugeto Array BioPharma Inc.(303) 386-1193thaugeto@arraybiopharma.com
'/>"/>

SOURCE Array BioPharma
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Global Array Instrument Market is Expected to Reach USD 3.2 Billion Globally in 2017: Transparency Market Research
2. Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2013
3. Array BioPharma To Present Clinical Data On ARRY-797 At The 2012 American College Of Rheumatology Annual Meeting
4. Array BioPharma Announces Proposed Public Offering Of Common Stock
5. Array BioPharma Announces Pricing Of Public Offering Of Common Stock
6. Array BioPharma To Present At The Piper Jaffray Annual Healthcare Conference
7. InternetArray Collaborates with Health Sciences Group to Fund Medical Marijuana Social Media/Mobile Apps Development
8. Array BioPharma To Present At The Leerink Swann Global Healthcare Conference
9. Zacks Bull and Bear of the Day Highlights: Fortune Brands Home & Security, Wal-Mart Stores, Regeneron Pharmaceuticals, Bayer and Array Biopharma
10. Array BioPharma To Present At The Cowen Annual Health Care Conference
11. Array BioPharma Names Michael N. Needle, M.D. As Chief Medical Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/9/2017)... 2017 Dealmed Medical Supplies, New ... equipment, supplies, drugs, vaccines, and specialty medical products and ... agreement to acquire Vantage Medical Supplies, a major distributor ... Holtsville, New York . ... emerging medical practices, will operate under the Dealmed name ...
(Date:9/7/2017)... Sept. 7, 2017  For nearly two decades, New Life Agency has ... Reproduction Insurance industry. Today, New Life Agency announces a powerful three-way partnership ... ... ... http://pharmacarecard.com/ (PRNewsfoto/PharmaCareCard) ...
(Date:9/7/2017)... 7, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Morgan ... the Grand Hyatt hotel in New York.  Zimmer Biomet ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .   ...
Breaking Medicine Technology:
(Date:9/21/2017)... FL (PRWEB) , ... September 21, 2017 , ... 38-Year-Old ... Aesthetic Surgery Center in Naples, Florida is pleased to announce that Plastic Surgeon Kiranjeet ... Top 40 Under 40 is an annual award that was started in ...
(Date:9/21/2017)... Chicago, IL (PRWEB) , ... September 21, 2017 , ... ... set to run from September 11 to the end of November. , The Chicago, ... out to their community and teach them about the ease of taking their personal ...
(Date:9/21/2017)... ... September 21, 2017 , ... Promotional ... http://www.fdanews.com/products/54818-promotional-communication      , In the competitive world of drug and device marketing ... in compliance with FDA rules. , The FDA has issued two draft guidances ...
(Date:9/21/2017)... ... September 21, 2017 , ... Demonstrating a consistent and ... departments have been awarded five-year accreditation status through the Public Health Accreditation ... served by a PHAB-accredited health department now extend to more than 203 ...
(Date:9/21/2017)... ... 21, 2017 , ... In addition to sticking with the ... holistic approach and use natural alternatives for all house cleaning products, disinfectants, respiratory ... guaranteeing that, the new line of essential oils, are all 100% organic and ...
Breaking Medicine News(10 mins):